Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
The Bottom Line - Jan 21 2016 - By Adrian Wong
Abdul-Aziz. ICM 2016; doi:10.1007//s00134-015-4188-0
"Clinical Question
- In adult ICU patients with severe sepsis does the use of continuous infusion (CI) of beta-lactam antibiotics compared to intermittent bolus (IB) improve clinical outcomes?
The Bottom Line
- This study confirms that CI has a superior PK/PD profile compared to IB regiments
- The higher clinical cure rate, ventilator free days and faster resolution of white cell count in the CI group did not translate to a mortality benefit at both 14 and 30 days
- Given the weakness in this study and the simplicity of IB regiment, I will continue to use this in my daily practice"
External Links
- [article] Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
- [further reading] A multicenter randomized trial of continuous versus intermittent beta-lactam infusions in severe sepsis
- [further reading] Alternative dosing strategies for intravenous antibiotics to treat severe infections
- [further reading] LITFL CCC - Antimicrobial dosing and kill characteristics